Inv(16)(p13q22) and the related translocation t(16;16)(p13;q22) generate a CBFB-MYH11 fusion gene transcript and are commonly found in acute myeloid leukemia (AML) M4Eo. 1 This recurrent chromosomal anomaly is considered a good risk marker, associated with a high complete remission rate and a long-term disease-free survival. 2 Nevertheless, a considerable proportion of patients suffer from relapse. Analysis of minimal residual disease (MRD) may allow recognition of patients at high risk of relapse and/or may detect an upcoming relapse. Buonamici et al 3 used real-time quantitative PCR (RQ-PCR) analysis and suggested the existence of cutoff points in CBFB-MYH11 þ AML beneath which durable remission is likely or above which relapse is probable. Schnittger et al 4 proposed a risk stratification score for CBFB-MYH11 þ AML based on the quantification of fusion gene transcripts at diagnosis and after consolidation. So far, most MRD studies in CBFB-MYH11 þ AML patients mainly used bone marrow (BM) samples. To evaluate the possibility to safely replace BM by peripheral blood (PB) for PCR-MRD monitoring in clinical settings, comparing RQ-PCR results of paired PB-BM samples is essential. For specific subtypes of AML, such as the t(8;21)-positive AML with AML1-ETO transcripts, the possibility of MRD monitoring through quantitative analysis of PB has been reported. 5, 6 Gallagher et al 7 reported on the prognostic value of RQ-PCR of PML-RARA transcripts and showed that paired PB-BM samples had comparable MRD levels. They suggested that RQ-PCR for PML-RARA performed on PB at frequent follow-up points may improve predictive accuracy for relapse or continuing complete remission. Whether MRD monitoring of PB is of prognostic relevance in CBFB-MYH11 þ AML patients is, however, still unknown.
In this study, we quantified by RQ-PCR the CBFB-MYH11 transcripts in 128 PB and 67 BM samples, including 64 paired PB-BM samples taken on the same day, from 10 different CBFB-MYH11 þ AML patients. Patients' characteristics, type of breakpoint, cytogenetic data, treatment and clinical outcome are summarized in Table 1 . RQ-PCR was performed as described before. 8 Results were expressed as normalized copy numbers (NCN): (numbers of CBFB-MYH11 transcripts/numbers of b-glucuronidase (GUS) transcripts) Â 10 4 . CBFB-MYH11À samples with less than 1000 transcripts of GUS were excluded from further analyses; this concerned four PB samples, two of which had a corresponding BM sample. At least three PB and two BM samples were analyzed per patient with a mean of 13 PB and six BM samples. The median follow-up was 27.5 months (range: 1.5-66 months). The number of samples and the timing of sampling were not uniform among patients due to the retrospective nature of our study.
CBFB-MYH11 transcript levels in eight diagnostic paired PB-BM samples showed no significant difference between both sample types ( Figure 1 ). Out of 54 paired PB-BM samples obtained during follow-up, 16 pairs were MRD negative in both BM and PB, while in 27 pairs, MRD was detected in both BM and PB. In the remaining 11 paired follow-up samples, MRD was detected only in BM, but not in the corresponding PB. MRD levels in the 54 follow-up PB-BM pairs showed a moderate correlation (Spearman's correlation, r s ¼ 0.82): MRD levels in BM were generally higher than in PB, with a variable ratio between the MRD level in the BM sample and the corresponding PB sample, ranging from 0.8-up to almost 100-fold (Figure 1 ). This variable range implies that no straightforward relationship exists between MRD levels in paired PB and BM samples of CBFB-MYH11 þ AML patients during follow-up. The generally higher MRD levels in BM are in line with the fact that AML has its origin in BM. Although CBFB-MYH11 transcript levels in follow-up PB did not precisely reflect MRD levels in the corresponding BM samples, monitoring of CBFB-MYH11 transcripts in PB did have clinical and predictive value, as illustrated by the evolution and outcome of our 10 patients. Induction therapy resulted in a mean transcript reduction of 3.2 and 3.9 log in BM and PB, respectively. The second cycle induced a mean tumor load reduction of 0.7 log in BM and 1.0 log in PB. After this second course, there were no molecular remissions in the BM samples. However, the molecular results of eight patients with PB followup samples, available after the second course, were as follows: three patients showed a molecular remission and stayed in longterm remission, while five patients had residual disease. In the five patients with MRD positivity in their PB after the second course, four relapses were seen (Figure 2 ): two patients suffered from an early BM relapse (patients 3 and 5), one patient had a combined BM-CNS relapse (patient 8) and one patient had a seemingly isolated CNS relapse (patient 7). In addition, a late BM relapse was seen in patient 1 from whom no molecular PB data were available after the second course (Figure 2) . Thus, obtaining a molecular remission in PB after the second course may identify patients at low risk of relapse. In contrast to Schnittger et al, 4 no correlation was found between the diagnostic BM or PB transcript levels and clinical outcome, nor between BM or PB tumor load reduction after induction or second course and clinical outcome, which might be due to the limited number of patients in our study.
In addition to providing prognostic information, MRD analysis may also be used for early detection of a (molecular) relapse. Indeed, all patients with a cytological BM relapse (patient 1, 3, 5 and 8) showed a significant (X1 log) increase of CBFB-MYH11 transcripts in their PB 2.5-4 months before cytological relapse (Figure 2 ). The patient who experienced an isolated CNS relapse (patient 7), after a molecular remission of 13 months in BM and PB, showed at the time of the CNS relapse low transcript levels in the BM; 1 month later, also the PB became positive (Figure 2 ).
In conclusion, our results show that there is no straight correlation between MRD levels in PB samples and the corresponding BM samples during follow-up in CBFB-MYH11 þ AML. Nevertheless, monitoring of CBFB-MYH11 transcript levels in PB can have potential clinical value. Firstly, CBFB-MYH11À PB samples after the second course might predict a favorable prognosis with long-term remission. Secondly, CBFB-MYH11 levels in follow-up PB samples can predict disease reoccurrence 2.5-4 months prior to cytological BM relapse (Figure 2 ). Although analysis of BM could predict these relapses in some patients up to 2 months earlier, we believe that in practice a time frame of at least 2.5 months should be enough to adjust therapy in order to prevent the occurrence of a cytological relapse. Treatment intervention at the time of molecular relapse may result in better clinical outcome than treatment at the time of overt clinical relapse. This approach was proven to be successful for PML-RARA þ patients. 9 Also for CML after allogeneic transplantation, it has been proven that patients benefit from early intervention with donor lymphocyte infusions at the time of cytogenetic relapse. 10 Based on our preliminary data, we propose that patients with a CBFB-MYH11 þ AML can be monitored through regular evaluation of their PB at set points, thereby avoiding multiple invasive BM punctures. Such PB examinations could be performed every 2-3 months after consolidation and BM should be examined in case of rising CBFB-MYH11 transcripts in PB. However, further studies in a large population of uniformly treated patients with the collection of paired PB-BM samples at specific time points are needed to determine the precise clinical value of PB samples for disease monitoring, as well as the optimal time interval between consecutive PB samples that allow a reliable early detection of molecular relapses in CBFB-MYH11 þ AML. In addition, current therapeutic protocols should include treatment intervention at the time of molecular relapse, since this might improve patient outcome. 
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